Allergan Presents Data From Seventeen Abstracts At The 2017 American Society For Dermatologic Surgery Meeting In Chicago

DUBLIN, Oct. 5, 2017 /PRNewswire/ -- Allergan (NYSE: AGN), a leading global pharmaceutical company, announced today that it will present 17 Allergan-supported abstracts at the 2017 American Society for Dermatologic Surgery (ASDS) meeting in Chicago, Illinois from October 5-8.

The meeting will be held at the Exhibit Hall, Riverside Center and the scheduled times (noted in local Central Time) of the Allergan presentations, titles and authors are as follows:

Real-World Use of ATX-101 Treatment for Reduction of Submental Fat: Final Data from CONTOUR

• Authors: Beer K, Callender VD, Shridharani SM, Schlessinger J, Teller CF, Chen J, Gallagher CJ
• Poster Presentation
• Thursday, 10/7, 5:30- 7:00 PM

Improvements in Submental Contour Achieved With ATX-101 Treatment Are Maintained Over Time: 3-Year Follow-up of Subjects from the Phase 3 REFINE Trials

• Authors: Humphrey S, Bhatia AC, Green LJ, Cohen JL, Green JB, Liu C, Somogyi C
• Poster Presentation
• Thursday, 10/5, 5:30- 7:00 PM

OnabotulinumtoxinA for Treatment of Moderate to Severe Horizontal Frontalis Lines and Glabellar Lines from the Subject's Perspective: Patient-Reported Satisfaction and Impact Outcomes from a Phase 3 Double-Blind Study

• Authors: Dayan S, Ogilvie P, Rivkin ; Yoelin S, Ferrusi I 
• Poster Presentation
• Thursday, 10/5, Noon- 7:00 PM; Friday, 10/6, 10:00 AM- 7:00 PM; Saturday, 10/7, 9:00 AM-2:00 PM

Simultaneous Treatment of Moderate to Severe Horizontal Frontalis Lines, Glabellar Lines, and Lateral Canthal Lines With OnabotulinumtoxinA from the Subject's Perspective: Patient-Reported Satisfaction and Impact Outcomes from a Phase 3 Double-Blind Study

• Authors: Dayan S, Ogilvie P, Rivkin ; Yoelin S, Ferrusi I
• Poster Presentation
• Thursday, 10/5, Noon- 7:00 PM; Friday, 10/6, 10:00 AM- 7:00 PM; Saturday, 10/7, 9:00 AM-2:00 PM

Efficacy and Safety of OnabotulinumtoxinA for Treatment of Moderate to Severe Forehead Lines

• Authors: Fagien S, Cohen JL, Coleman W, Monheit G, Carruthers J, Mao C, Vitarella D, Lei X, Hardas B
• Poster Presentation
• Thursday, 10/5, Noon- 7:00 PM; Friday, 10/6, 10:00 AM- 7:00 PM; Saturday, 10/7, 9:00 AM-2:00 PM 

OnabotulinumtoxinA (Botox^®) Displays Superior Activity to IncobotulinumtoxinA Drug Product (Xeomin^®) in Multiple in Vitro and in Vivo Assays

• Authors: Canty D, Le L, Wang J, Nicholson G, Brideau-Andersen A, Steward L, Jacky B, Broide R, Washburn M, Rupp D 
• Poster Presentation
• Thursday, 10/5, Noon- 7:00 PM; Friday, 10/6, 10:00 AM- 7:00 PM; Saturday, 10/7, 9:00 AM-2:00 PM 

The Psychological Impacts of Forehead, Glabellar, and Lateral Canthal Lines: Qualitative, Patient-Centered Studies

• Authors: S Dayan, S Yoelin, K De Boulle, I Ferrusi
• Oral Presentation
• Thursday, 10/5, 5:05- 5:10 PM

Juvéderm Vollure XC Is Safe and Effective for Long-term Correction of Nasolabial Folds: Results from a Multicenter, Randomized, Controlled Study

• Authors: Dayan S, Maas CS, Grimes PE, Beer K, Monheit G, Hardas B, Lin V
• Oral Presentation
• Saturday, 10/7, 10:30 AM-10:35 AM

VYC-17.5L is Effective for the Treatment of Static and Dynamic Radial Cheek Lines: Results from the BEAM Study

• Authors: Ogilvie P, Fink B,  Leys C, Godlewska S, Niforos F, Kerson G, Silberberg M
• Poster Presentation
• Thursday, 10/5, Noon- 7:00 PM; Friday, 10/6, 10:00 AM- 7:00 PM; Saturday, 10/7, 9:00 AM-2:00 PM 

VYC-17.5L is Safe and Effective for Long-Term Correction of Nasolabial Folds: Results from a Multicenter, Randomized, Controlled Study

• Authors: Dayan S, Maas CS, Grimes PE, Beer K, Monheit G, Hardas B, Lin V
• Oral Presentation
• Saturday, 10/7, 10:30 AM-10:35 AM

Lip and Perioral Enhancement With HA Dermal Fillers in Individuals With Skin of Color

• Authors: Taylor s, Downie S, Shamban A, Few J, Schumacher A, Gallagher C
• Poster Presentation
• Thursday, 10/5, Noon- 7:00 PM; Friday, 10/6, 10:00 AM- 7:00 PM; Saturday, 10/7, 9:00 AM-2:00 PM 

Maximizing Panfacial Aesthetic Outcomes: Findings and Recommendations from the HARMONY Study

• Authors: Kaminer M, Cohen J, Narurkar A, Shamban A, Werschler W, Shumate G, Gallagher C
• Oral Presentation
• Thursday, 10/5, 11:35-11:40 AM

Differential Facial Aesthetic Treatment Considerations for Skin of Color Populations: African American, Asian and Hispanic

• Authors: Boyd C, Chiu A, Montes JR, Narurkar V, Shumate GT, Gallagher CJ
• Poster Presentation
• Thursday, 10/5, Noon- 7:00 PM; Friday, 10/6, 10:00 AM- 7:00 PM; Saturday, 10/7, 9:00 AM-2:00 PM 

Skin Laxity Is Unchanged Among ATX-101 Treatment Responders: Post hoc Analysis of Phase 3 Data

• Authors: Fabi S, McDiarmid J, Benito-Ruiz J, Bass LS, Jones DH, Orejudos A, Gallagher CJ, Somogyi C
• Podium Presentation
• Saturday, 10/7, 10:15-10:20 AM

Reduction of Submental Fat Continues Beyond 28 Days After ATX-101 Treatment: Results from a Post hoc Analysis

• Authors: Dover JS, Shridharani SM, Bloom JD, Gallagher CJ, Somogyi C
• Featured In Program Book

Efficacy and Safety of OnabotulinumtoxinA for Moderate to Severe Forehead Lines in Subjects With Upper Facial Lines

• Authors: De Boulle K, Werschler P, Gold MH, Bruce S, Sattler G, Ogilvie P, Mao C, Vitarella D, Lei S, Hardas B
• Featured In Program Book

A Customized Approach for Arm Fat Reduction using Cryolipolysis

• Authors: Rivers J, Ulmer M, Vestvik B, Santos S
• Featured In Program Book

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model ? Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline programs currently in development.

Allergan's success is powered by our more than 18,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended June 30, 2017. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

© 2017 Allergan. All rights reserved. All trademarks are the property of their respective owners.

CONTACTS:      
Allergan:
Investors:
Daphne Karydas
(862) 261-8006

Media:
Mark Marmur
(862) 261-7558

Ember Garrett
(714) 246-3525

SOURCE Allergan plc